DUBAI, UAE, August 17, 2017 /PRNewswire/ --
Hikma Pharmaceuticals PLC
(Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast
growing multinational pharmaceutical group, through its
wholly-owned subsidiary Hikma Pharmaceuticals LLC has reached an
agreement with Takeda Pharmaceutical Company Limited (Takeda) to
expand its licensing and distribution agreement with the global
research and development-driven pharmaceutical company, adding
new products to its portfolio in the Middle East and North Africa (MENA). Hikma will have
the right to register, manufacture, market, distribute and sell
four of Takeda's leading primary care products in 17 markets in the
MENA region.
Under the terms of the agreement, which is effective immediately
for all markets, Hikma has the exclusive rights to
manufacture and commercialise three of Takeda's leading primary
care product families - Alogliptin, including Alogliptin/Metformin,
Alogliptin/Pioglitazone (anti-diabetic), Azilsartan, including
Azilsartan/Chlorothalidone (anti-hypertensive) and Lornoxicam in
its rapid form (anti-inflammatory/ pain) - in its MENA markets. The
agreement, however, does not include the Egyptian market for
Alogloptin. Hikma also has exclusive rights to manufacture
and commercialise Takeda's Dexlansoprozole in its MENA markets,
with the exception of Saudi
Arabia, the UAE and Egypt.
Hikma's existing license agreement with Takeda in respect of
Lornoxicam tablets (anti-inflammatory/ pain), has been expanded
beyond Saudi Arabia and
Jordan to cover Hikma's
other MENA markets.
The new agreement builds on a long-standing strategic
partnership between Hikma and Takeda. It leverages
Hikma's substantial sales and manufacturing presence in the
MENA and extensive experience of building brands in the region.
Mazen Darwazah, Executive Vice Chairman and CEO of MENA and
Emerging Markets said, "Our large sales and marketing teams, with
particular expertise in promoting cardiovascular and diabetes
treatments, are well positioned to drive strong demand for Takeda's
products. We are pleased to be building on our partnership
with Takeda to bring important medicines to the MENA region.
By working with global partners we are strengthening our
product portfolio in growing therapeutic areas and reinforcing our
commitment to improving patient access to quality medicines."
In turn, Danilo Cassani, Takeda's
Vice President and Area Head Near East, Middle East & Africa said, "At Takeda, we put patients at
the centre of everything we do. As such, our partnership with
Hikma is a testament of our commitment to offer patients
world-class cardiovascular and metabolism (CVM) medicines
while keeping focus on our core therapeutic areas of oncology and
gastroenterology. This will help better serve the unmet medical
needs of patients."
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics", based primarily in the
Middle East and North Africa ("MENA") region, where it is a
market leader, the United States
and Europe. Hikma currently
employs over 8,500 staff members worldwide.
For further information and latest news updates, visit
http://www.Hikma.com or contact:
Hana Darwazeh Ramadan
Email: Media@Hikma.com
Tel: +962-6-580-2900
About Takeda
Takeda Pharmaceutical Company Limited is a global, research and
development-driven pharmaceutical company committed to bringing
better health and a brighter future to patients by translating
science into life-changing medicines. Takeda focuses its R&D
efforts on oncology, gastroenterology and central nervous system
therapeutic areas plus vaccines. Takeda conducts R&D both
internally and with partners to stay at the leading edge of
innovation. New innovative products, especially in oncology and
gastroenterology, as well as our presence in Emerging Markets, fuel
the growth of Takeda. More than 30,000 Takeda employees are
committed to improving quality of life for patients, working with
our partners in health care in more than 70 countries. For more
information, visit http://www.takeda.com/news.
For more
information or assistance, please contact us at:
FTI Consulting
Shane Dolan
Managing Director - Strategic Communications
Email: Shane.dolan@fticonsulting.com
Tel: +971-4-437-2100